Teva Pharmaceutical Industries (NYSE:TEVA) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Teva Pharmaceutical Industries (NYSE:TEVA) announced its earnings results on Tuesday. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.72 by $0.14, FiscalAI reports. The firm had revenue of $4.39 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.78 earnings per share.

Teva Pharmaceutical Industries Stock Down 3.0%

NYSE TEVA opened at $40.84 on Tuesday. Teva Pharmaceutical Industries has a 12 month low of $20.11 and a 12 month high of $42.59. The company has a market capitalization of $47.59 billion, a P/E ratio of 18.33, a PEG ratio of 3.71 and a beta of 0.89. The company’s 50 day simple moving average is $39.14 and its 200 day simple moving average is $34.59. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67.

Insider Buying and Selling

In other news, Director Roberto Mignone sold 367,600 shares of the stock in a transaction on Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian Savage sold 7,342 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the sale, the insider directly owned 8,500 shares of the company’s stock, valued at approximately $330,225. This represents a 46.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 374,959 shares of company stock valued at $14,644,285 over the last 90 days. 0.54% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TEVA. Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Barclays boosted their price objective on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an “overweight” rating in a research note on Thursday, October 15th. Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. TD Cowen assumed coverage on Teva Pharmaceutical Industries in a research note on Thursday, October 1st. They set a “buy” rating and a $55.00 target price for the company. Finally, UBS Group raised their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $46.54.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q3 earnings beat expectations: Teva reported adjusted earnings of $0.86 per share, versus the $0.72 analyst consensus, while revenue of approximately $4.39 billion exceeded expectations of $4.23 billion. Revenue declined 1.9% year over year, but the earnings and sales beats provide support for the stock. Teva Pharmaceutical Q3 profit gain beats estimates
• Positive Sentiment: UZEDY momentum strengthened: U.S. net sales of the schizophrenia treatment reached $85 million in the third quarter, up 96% year over year. Teva raised its 2026 UZEDY revenue outlook to $290–$310 million from $270–$290 million, signaling stronger growth for a key branded product. Medincell UZEDY third-quarter sales and outlook
• Positive Sentiment: Biosimilar portfolio expanded: Teva signed an agreement with Samsung Bioepis to commercialize two FDA-approved U.S. immunology biosimilars. ETICOVO rights transfer upon closing, while infliximab-abda is expected to become available in the third quarter of 2027, supporting Teva’s generics and biosimilars strategy. Teva and Samsung Bioepis biosimilar agreement
• Positive Sentiment: Analyst endorsement: HC Wainwright initiated coverage with a “buy” rating and a $52 price target, implying meaningful potential upside from the referenced share price.
• Negative Sentiment: Neuroscience setback: Teva will discontinue the Phase 2 TOPAS-MSA study of emrusolmin for multiple system atrophy after an interim futility analysis indicated a low probability of meeting the primary efficacy endpoint. Although no safety concerns were identified, the decision removes a potential pipeline catalyst and was the primary source of selling pressure. Teva discontinues emrusolmin Phase 2 study

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.